šMedical science cannot revoke its responsibility for complications that occur from the use of gadolinium-based contrast agents. There are undiscovered factors
Dec 15, 2022 ā¢ 7 tweets ā¢ 4 min read
š§µ1. Thank you to the partners who have provided financial support to the the Kidney Institute of New Mexico.
unmfund.org/fund/unm-kidneā¦
š§µ2. Your donations have directly translated into essential discoveries leading to improved human health. We appreciate the genuine relationship with our supporters and research participants.
Now: āDialyzing the Undocumented: Driving Policy with Dataā
by Dr. Lilia Cervantes, M.D.
Denver Health Medical Center and the University of Colorado Anschutz Medical Group @Cervantes_Lily1 University of New Mexico Health Science Center Department of Medicine Grand Rounds
āPatients sometimes consumed foods [knowingly] high in potassium,ā in order to gain admission ā @Cervantes_Lily1 University of New Mexico Health Science Center Department of Medicine Grand Rounds
Oct 5, 2019 ā¢ 4 tweets ā¢ 5 min read
āAround 2012 or 2013, researchers identified evidence that gadolinium retention was connected to illness in patients with normal kidney function.ā scholar.google.com/scholar_case?cā¦
āIn September 2017, after the FDA voted to add concerns about gadolinium retention on warning labels, [gadolinium-based contrast agent] manufacturers, including Defendants, issued a new joint warning to patients with normal kidney function.ā scholar.google.com/scholar_case?cā¦
The āAmerican College of Radiology] Committee on Drugs and Contrast Media considers the risk of [ānephrogenicā systemic fibrosis] among patients exposed to standard or lower than standard doses of group II [gadolinium-based contrast agents] is ... possibly nonexistent...ā
May 13, 2019 ā¢ 11 tweets ā¢ 16 min read
āGadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors,ā is now in pressāsciencedirect.com/science/articlā¦
ā[I]t is known that during those at least 6 weeks [after exposure to gadolinium-based contrast agent] equilibrium has not been reached and [gadolinium] can be measured for all [gadolinium-based contrast agents] in tissue,ā fda.gov/downloads/Adviā¦
#gadolinium
š§
ā¢ļø
āIt is important to note that the exact mechanism and in particular other co-factors that are likely needed to trigger [ānephrogenicā systemic fibrosis] are still unknown,ā fda.gov/downloads/Adviā¦
āA conspicuous knowledge gap now exists aboutā the safety of gadolinium-based contrast agentsāDr. Stephen Brown, Harvard Medical School, in
The Need for National Guidance Around Informed Consent About GBCA Safety tandfonline.com/doi/abs/10.108ā¦ #gadolinium#radiology#patientsafety
āThe research protocol under discussion highlights where the [National Institutes of Health] Roadmap around [gadolinium-based contrast agents] falls short,ā because informed consent about gadolinium deposition could be left outāDr. Stephen Brown tandfonline.com/doi/abs/10.108ā¦
Apr 16, 2019 ā¢ 14 tweets ā¢ 25 min read
āDespite significant differences in the thermodynamic stability between non-ionic Omniscan and ionic Magnevist, the [#gadolinium ā ļø] concentrations were about the same in the brain,ā nibib.nih.gov/sites/default/ā¦ #radiology ā¢ļø #patientsafety#publichealth#neurology š§ #dermatology
āChronic symptoms attributed to [gadolinium-based contrast agent] exposure:ā paresthesias, dysesthesias, clouded mentation, skin discoloration, skin changes, skin thickening, bone pain, bone/joint pain, muscle spasms, arthralgia, muscular weaknessānibib.nih.gov/sites/default/ā¦
